OakChart

Pharvaris NV

PHVSHealthcare·Biotechnology·Netherlands·Mid·NASD·Nov 11 • 3:59 PM ET

34.18+0.19 (0.56%)
2026-11-12 00:12 CET
Market cap
2,386.25 USD m
Revenue, TTM
0.00 USD m
Net income, TTM
-199.29 USD m
Free cash flow, TTM
-182.73 USD m
EPS diluted, TTM
-3.05
P/E
-
Compare

Price

PHVS against its 20, 50 and 200-day averages
2050200beatmiss
25.0030.0035.0040.003.2M6.3MVolumeMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26PHVSclose 34.1820-day 32.3250-day 33.32200-day 31.2834.1852w high

21.0% under the 52-week high of 43.25 on 8 Sep 2026. 52-week low 22.41 on 11 Nov 2025. Last 15 sessions, 18.9% high to low

Volume 0.52× normal · the line is the 50-bar volume average

Profile

PHVS
52-week range, 56% of the way up
22.4143.25

Pharvaris NV is a clinical-stage company, which engages in bringing oral bradykinin B2-receptor antagonists to patients. It focuses on the development and commercialization of innovative therapies for rare diseases focused on angioedema and other bradykinin-mediated diseases. The company was founded by Luc Dochez, Jens Schneider-Mergener, Berndt A. E. Modig, Jochen Knolle, Johannes Gerardus Christiaan Petrus Schikan, and Anne Lesage on September 30, 2015 and is headquartered in Leiden, the Netherlands.

Employees129
IPOFeb 05, 2021
Beta-2.50
ATR, 14d1.55
Rel volume0.52
Short float7.52%
Insider own51.90%
Inst own47.89%

Snapshot

6 groups

Valuation

Index-
Market Cap2.40B
Enterprise Value2.04B
Income-199.29M
Sales0.00M
Book/sh4.90
Cash/sh5.18
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees129
IPOFeb 05, 2021

Ratios

P/E-
Forward P/E-
PEG-
P/S-
P/B6.98
P/C6.59
P/FCF-
EV/EBITDA-
EV/Sales-
Quick Ratio11.94
Current Ratio11.94
Debt/Eq0.00
LT Debt/Eq0.00
Option/ShortYes / Yes

Earnings

EPS (ttm)-3.05
EPS next Y-3.03
EPS next Q-0.81
EPS this Y5.40%
EPS next Y3.56%
EPS next 5Y33.53%
EPS past 3/5Y-11.96% -21.68%
Sales past 3/5Y- -
EPS Y/Y TTM9.42%
Sales Y/Y TTM-
EPS Q/Q13.30%
Sales Q/Q-
EarningsAug 12 BMO
EPS/Sales Surpr.-8.70% -

Ownership

Insider Own51.90%
Insider Trans-2.01%
Inst Own47.89%
Inst Trans10.29%
ROA-64.08%
ROE-71.14%
ROIC-57.86%
Gross Margin-
Oper. Margin-
Profit Margin-
SMA205.75%
SMA502.60%
SMA2009.27%
Trades-

Technical

Shs Outstand70.20M
Shs Float33.77M
Short Float7.52%
Short Ratio3.15
Short Interest2.54M
52W High43.25 -20.97%
52W Low22.41 52.49%
Volatility6.51% 4.77%
ATR (14)1.55
RSI (14)57.23
Beta-2.50
Rel Volume0.52
Avg Volume806.58K
Volume421,707

Performance

Perf Week-0.44%
Perf Month13.86%
Perf Quarter0.41%
Perf Half Y3.76%
Perf YTD23.17%
Perf Year41.71%
Perf 3Y94.20%
Perf 5Y113.63%
Perf 10Y-
Recom1.00
Target Price57.51
Prev Close33.99
Price34.18
Change %0.56%

Analyst ratings

latest 10 of 19
DateActionAnalystRating changeTargetImplied
Oct 23, 2026UpgradeBBofA SecuritiesNeutral → Buy$44+28.7%
Jul 15, 2026InitiatedWWells FargoOverweight$55+60.9%
Apr 09, 2026InitiatedWWolfe ResearchOutperform$42+22.9%
Mar 09, 2026InitiatedRRBC Capital MktsOutperform$52+52.1%
Oct 15, 2025InitiatedHH.C. WainwrightBuy$60+75.5%
Oct 09, 2025UpgradeBBofA SecuritiesUnderperform → Neutral$27-21.0%
Jun 11, 2025InitiatedGGuggenheimBuy$32-6.4%
Apr 29, 2025InitiatedCCantor FitzgeraldOverweight$28-18.1%
Sep 25, 2023InitiatedWWedbushOutperform$27-21.0%
Aug 15, 2023UpgradeMMorgan StanleyEqual-Weight → Overweight$10 → $34-0.5%

Peers

Mkt cap
TickerCompanyMkt cap
PHARPharming Group NV ADR948.45M
BCRXBiocryst Pharmaceuticals Inc1.97B
IONSIonis Pharmaceuticals Inc4.72B
NTLAIntellia Therapeutics Inc1.60B
ADRXADARx Pharmaceuticals Inc1.47B
TAKTakeda Pharmaceutical Co ADR66.58B
MIRMMirum Pharmaceuticals Inc6.18B
VERAVera Therapeutics Inc2.20B
ADMAAdma Biologics Inc2.93B
AUPHAurinia Pharmaceuticals Inc2.17B

Insider trading

latest 14 of 100
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
Monges VivianeDirectorSep 23 '26Option Exercise8.0511,96996,35017,469Sep 25 01:35 PM
Monges VivianeDirectorSep 23 '26Sale33.0511,969395,5245,500Sep 25 01:35 PM
Lu PengPresidentSep 22 '26Option Exercise2.5945,308117,348110,261Sep 24 04:03 PM
Schikan Johannes Gerardus ChriDirectorSep 22 '26Option Exercise20.0080016,000115,967Sep 24 10:43 AM
Schikan Johannes Gerardus ChriDirectorSep 22 '26Sale36.1980028,952115,167Sep 24 10:43 AM
VIVIANE ROSINE FRANCOISE BECKDirectorSep 23 '26Proposed Sale33.0511,969395,524Sep 23 04:24 PM
Nassif David W.CFO / CLOSep 21 '26Sale36.476,000218,801114,300Sep 23 10:06 AM
JOHANNES GER. CHRIS. PE SCHIKADirectorSep 22 '26Proposed Sale36.1980028,952Sep 22 04:13 PM
Lu PengPresidentSep 17 '26Option Exercise2.59100,000259,000164,953Sep 21 04:20 PM
Lu PengPresidentSep 17 '26Sale35.00100,0003,500,00064,953Sep 21 04:20 PM
Schikan Johannes Gerardus ChriDirectorSep 17 '26Sale35.00200,0007,000,000115,167Sep 21 04:18 PM
DAVID NASSIFOfficerSep 21 '26Proposed Sale36.476,000218,801Sep 21 04:06 PM
Bjork ElisabethDirectorSep 17 '26Option Exercise15.6452,500821,10067,667Sep 21 03:20 PM
Bjork ElisabethDirectorSep 17 '26Sale37.8952,5001,989,40915,167Sep 21 03:20 PM

Held by

AUM
TickerCompanyAUM
IBBiShares Biotechnology ETFAUM: 11.36B
IEFAiShares Core MSCI EAFE ETFAUM: 191.66B
SCZiShares MSCI EAFE Small-Cap ETFAUM: 12.92B
EWNiShares MSCI Netherlands ETFAUM: 608.75M
ONEQFidelity Nasdaq Composite Index ETFAUM: 10.35B
SMLFiShares U.S. Small-Cap Equity Factor ETFAUM: 4.26B
BBCVirtus Biotech Clinical Trials ETFAUM: 31.26M
IEURiShares Core MSCI Europe ETFAUM: 9.81B
FMEDFidelity Disruptive Medicine ETFAUM: 30.30M
IBBQInvesco Nasdaq Biotechnology ETFAUM: 130.27M

News

latest 14 of 200

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q22026-08-12-0.808-0.743-0.7810.000.0012
2026Q12026-05-12-0.692-0.835-0.7020.000.0011
2025Q42026-04-02-0.835-0.707-0.8340.000.0011
2025Q32025-11-12-0.698-0.768-0.6970.000.0010
2025Q22025-08-12-0.969-0.875-0.9430.000.009
2025Q12025-05-13-0.951-0.874-0.8950.000.008
2024Q42025-04-07-0.703-0.752-0.6830.000.007
2024Q32024-11-13-0.814-0.641-0.8470.000.007
2024Q22024-08-14-0.605-0.599-0.5930.000.006
2024Q12024-05-08-0.559-0.600-0.5660.000.004
2023Q42024-04-10-0.799-0.582-0.6730.000.006
2023Q32023-11-02-0.612-0.637-0.6280.000.006
2023Q22023-08-07-0.637-0.669-0.6900.000.004
2023Q12023-05-08-0.670-0.818-0.7180.000.003
2022Q42023-04-05-1.267-0.692-1.1820.000.005
2022Q32022-12-08-0.249-0.660-0.2530.000.005

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2020FY-4.691-4.442-1.2570.000.00
2021FY-1.554-2.372-1.6610.000.00
2022FY-2.480-1.894-2.3890.000.00
2023FY-2.825-2.415-2.8410.000.00
2024FY-2.724-2.727-2.6880.000.00
2025FY-3.442-3.184-3.2440.000.00
2026FY--3.137--0.00
2027FY--3.025--36.74
2028FY--0.974--246.82
2029FY-1.902--583
2030FY-5.606--961.89

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q3S2026-08-1210000.000.000.00
2026Q3S2026-05-1410000.000.000.00
2026Q3S2026-05-139000.000.000.00
2026Q3S2026-04-149000.000.000.00
2026Q3S2026-04-028000.000.000.00
2026Q3S2026-03-068000.000.000.00
2026Q3S2025-11-177000.000.000.00
2026Q3S2025-11-126000.000.000.00
2026Q3S2025-11-116000.000.000.00
2026Q3S2025-11-106000.000.000.00
2026Q3S2025-11-096000.000.000.00
2026Q3S2025-11-086000.000.000.00
2026Q3S2025-11-076000.000.000.00
2026Q3S2025-11-066000.000.000.00

Estimate history

EPS, annual-1.049-1.852-1.257-1.661-2.389-2.841-2.688-3.352-3.0508
Period20182019202020212022202320242025TTM
EPS, quarterly-0.593-0.847-0.683-0.895-0.943-0.697-0.834-0.702-0.817
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Sales, annual000000000
Period20182019202020212022202320242025TTM
Sales, quarterly000000000
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Shares, annual4.854.8523.56933.15233.81652.2954.37965.21170.205
Period20182019202020212022202320242025MRQ
Shares, quarterly54.00854.23354.37954.49354.73764.95965.21165.42470.205
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue0.000.000.000.000.000.000.000.000.00
Cost of Goods Sold Incl. D&A0.580.470.290.280.160.090.010.000.00
Gross Profit-0.58-0.47-0.29-0.28-0.16-0.09-0.01-0.000.00
Selling, General and Administrative Excl. Other212.03191.19157.30104.5090.9763.9028.508.965.09
Research and Development150.56140.48106.6270.8960.3042.3022.246.364.30
Other Operating Expense0.000.000.000.000.000.000.000.000.00
Operating Income-212.60-191.66-157.59-104.77-91.13-63.99-28.51-8.97-5.09
Interest Expense0.310.200.050.020.040.320.000.000.00
Unusual Expense0.000.000.000.000.000.000.000.000.00
Net Income Before Taxes-196.55-196.05-143.21-107.92-79.51-50.42-29.72-8.98-5.09
Income Taxes2.742.241.971.130.710.08-0.090.000.00
Consolidated Net Income-199.29-198.29-145.19-109.06-80.22-50.51-29.62-8.98-5.09
Net Income From Continuing Operations-199.29-198.29-145.19-109.06-80.22-50.51-29.62-8.98-5.09
Net Income-199.29-198.29-145.19-109.06-80.22-50.51-29.62-8.98-5.09
EPS (Recurring)-2.93-3.35-2.69-2.84-2.39-1.66-1.26-1.85-1.05
EPS (Basic, Before Extraordinaries)-3.05-3.35-2.69-2.84-2.39-1.66-1.26-1.85-1.05
EPS (Diluted)-3.05-3.35-2.69-2.84-2.39-1.66-1.26-1.85-1.05
EBITDA-212.03-191.19-157.30-104.50-90.97-63.90-28.50-8.96-5.09
Non-Operating Income (Expense)16.37-4.1914.43-3.1311.6713.88-1.21-0.02-0.00
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Stock Option Compensation Expense18.1315.9513.018.558.857.271.360.100.09
Shares Outstanding70.2065.2154.3852.2933.8233.1523.574.854.85
Market Capitalization2,386.252,386.251,035.331,146.03372.96476.72525.75--

Income statement, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q12024Q42024Q3
Total Revenue0.000.000.000.000.000.000.000.00
Cost of Goods Sold Incl. D&A0.210.120.120.120.120.110.100.05
Gross Profit-0.21-0.12-0.12-0.12-0.12-0.11-0.10-0.05
Selling, General and Administrative Excl. Other58.8451.6755.2846.2345.6444.2948.0041.59
Research and Development40.7035.2939.7434.8433.5632.5433.2828.32
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-59.05-51.80-55.40-46.35-45.76-44.40-48.10-41.64
Interest Expense0.080.100.070.060.040.030.020.01
Unusual Expense0.000.000.000.000.000.000.000.00
Net Income Before Taxes-54.93-45.54-52.47-43.61-51.32-48.45-35.76-45.57
Income Taxes0.700.321.94-0.210.230.321.320.25
Consolidated Net Income-55.63-45.86-54.40-43.40-51.55-48.77-37.08-45.82
Net Income From Continuing Operations-55.63-45.86-54.40-43.40-51.55-48.77-37.08-45.82
Net Income-55.63-45.86-54.40-43.40-51.55-48.77-37.08-45.82
EPS (Recurring)-0.82-0.70-0.83-0.70-0.94-0.90-0.68-0.85
EPS (Basic, Before Extraordinaries)-0.82-0.70-0.83-0.70-0.94-0.90-0.68-0.85
EPS (Diluted)-0.82-0.70-0.83-0.70-0.94-0.90-0.68-0.85
EBITDA-58.84-51.67-55.28-46.23-45.64-44.29-48.00-41.59
Non-Operating Income (Expense)4.216.353.002.80-5.52-4.0312.36-3.92
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense5.724.253.924.244.623.223.834.14
Shares Outstanding70.2065.4265.2164.9654.7454.4954.3854.23
Market Capitalization2,386.251,809.571,777.541,598.19959.08847.921,035.331,000.22

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Cash & Short Term Investments342.56290.69432.17172.72238.08120.6822.826.16
Short Term Receivables5.353.051.150.410.800.700.240.03
Inventories0.000.000.000.000.000.000.000.00
Other Current Assets3.455.956.164.941.922.270.050.03
Total Current Assets351.36299.69439.49178.07240.79123.6423.116.21
Net Property, Plant & Equipment1.641.530.500.670.400.060.010.00
Total Investments and Advances0.000.000.000.000.000.000.000.00
Intangible Assets0.000.000.000.000.000.000.000.00
Deferred Tax Assets1.040.490.430.28----
Other Assets0.000.000.000.000.000.000.000.00
Total Assets354.04301.72440.42179.01241.19123.7023.126.21
Short Term Debt Incl. Current Port. of LT Debt0.240.230.220.200.110.000.000.00
Accounts Payable6.014.723.216.382.420.800.570.28
Income Tax Payable1.110.620.470.490.140.23--
Other Current Liabilities27.4218.2112.2312.385.275.471.590.27
Total Current Liabilities34.7723.7916.1319.457.946.502.160.55
Long Term Debt0.680.660.050.270.170.000.000.00
Provision for Risks Charges0.000.000.000.000.000.000.000.00
Other Liabilities0.000.000.000.000.000.000.000.00
Total Liabilities35.4524.4516.1819.728.126.502.160.55
Non-Equity Reserves0.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.000.090.06
Common Equity318.60277.27424.24159.30233.07117.2020.875.60
Total Shareholders Equity318.60277.27424.24159.30233.07117.2020.965.66
Accumulated Minority Interest0.000.000.000.000.000.000.000.00
Total Equity318.60277.27424.24159.30233.07117.2020.965.66
Total Liabilities & Stockholders Equity354.04301.72440.42179.01241.19123.7023.126.21
Book Value Per Share4.895.108.114.717.034.974.301.16
Tangible Book Value Per Share4.895.108.114.717.034.974.301.16
Full-Time Employees1291088265349--
Price to Book Ratio6.943.147.092.102.893.19--
Return on Assets-60.48-39.13-35.21-38.18-27.68-40.35-61.26-
Return on Equity-66.56-41.39-37.38-40.89-28.84-42.88-67.49-
Return on Invested Capital-62.11-52.24-25.70-50.28-21.65-25.28-42.86-89.88
Quick Ratio10.1112.6027.259.1630.3119.0210.7011.29
Current Ratio10.1112.6027.259.1630.3119.0210.7011.29

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income-198.87-196.05-143.21-107.92-79.51-50.42-29.72-8.98-5.09
Depreciation0.580.470.290.280.160.090.010.000.00
Other Funds (Non Cash)12.3632.276.6113.39-0.04-4.253.410.130.12
Funds from Operations-185.94-163.30-136.31-94.26-79.39-54.58-26.30-8.86-4.97
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital3.338.606.37-6.348.801.861.791.380.34
Cash from Operating Activities-182.61-154.70-129.94-100.60-70.59-52.72-24.51-7.47-4.62
Capital Expenditures-0.12-0.19-0.58-0.10-0.13-0.15-0.05-0.020.00
Net Assets From Acquisitions0.000.000.000.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.000.000.000.00
Purchase or Sale of Investments0.000.000.000.000.000.000.000.000.00
Purchase of Investments0.000.000.000.000.000.000.000.000.00
Sale Or Maturity of Investments0.000.000.000.000.000.000.000.000.00
Other Uses0.000.000.000.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.000.000.000.00
Cash from Investing Activities-0.12-0.19-0.58-0.10-0.13-0.15-0.05-0.020.00
Cash Dividends Paid0.000.000.000.000.000.000.000.000.00
Change in Capital Stock310.33181.503.07352.039.22169.82115.3724.215.32
Repurchase of Common Pref Stock0.000.000.000.000.000.000.000.000.00
Sale of Common Pref Stock310.33181.503.07352.039.22169.82115.3724.215.32
Proceedsfrom Stock Options310.33181.503.07352.039.22169.82115.3724.215.32
Issuance or Reduction of Debt, Net0.000.000.000.000.000.000.000.000.00
Change in Long Term Debt-0.00-0.000.000.000.000.000.00
Issuance of Long Term Debt-0.00-0.000.000.000.000.000.00
Reduction of Long Term Debt-0.00-0.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.000.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.000.000.000.00
Cash from Financing Activities310.08181.262.90351.799.09169.82115.3724.215.32
Exchange Rate Effect8.32-14.018.10-3.0911.6913.93-1.55--
Net Change in Cash135.6712.36-119.53248.00-49.94130.8789.2616.720.70
Free Cash Flow-182.73-154.88-130.53-100.69-70.72-52.87-24.56-7.49-4.62
Preferred Dividends (Cash Flow)-0.000.000.000.000.000.00--
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Cash & Short Term Investments363.89284.55342.56386.91234.27255.46
Short Term Receivables6.035.735.353.453.052.86
Inventories0.000.000.000.000.000.00
Other Current Assets3.806.623.455.837.057.61
Total Current Assets373.72296.90351.36396.19244.36265.92
Net Property, Plant & Equipment1.381.561.641.471.571.63
Total Investments and Advances0.000.000.000.000.000.00
Intangible Assets0.000.000.000.000.000.00
Deferred Tax Assets0.660.861.040.540.350.40
Other Assets0.000.000.000.000.000.00
Total Assets375.77299.33354.04398.20246.29267.96
Short Term Debt Incl. Current Port. of LT Debt0.220.240.240.160.190.21
Accounts Payable3.193.126.012.995.704.56
Income Tax Payable0.001.111.111.000.680.64
Other Current Liabilities27.8821.9427.4226.6522.7718.54
Total Current Liabilities31.3026.4134.7730.8029.3523.96
Long Term Debt0.550.610.680.520.550.59
Provision for Risks Charges0.000.000.000.000.000.00
Other Liabilities0.000.000.000.000.000.00
Total Liabilities31.8527.0335.4531.3229.9024.55
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity343.92272.30318.60366.88216.38243.41
Total Shareholders Equity343.92272.30318.60366.88216.38243.41
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity343.92272.30318.60366.88216.38243.41
Total Liabilities & Stockholders Equity375.77299.33354.04398.20246.29267.96
Book Value Per Share4.904.164.895.653.954.47
Tangible Book Value Per Share4.904.164.895.653.954.47
Full-Time Employees148-129-114-
Price to Book Ratio6.945.004.916.313.942.57
Return on Assets-64.08-68.82-60.43-48.36-58.78-48.44
Return on Equity-71.14-75.71-66.50-51.80-63.95-51.85
Return on Invested Capital-16.15-16.80-17.04-11.81-23.76-19.99
Quick Ratio11.9411.2410.1112.868.3311.10
Current Ratio11.9411.2410.1112.868.3311.10

Cash flow, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Net Income-54.65-45.54-51.86-46.82-55.05-48.45
Depreciation0.210.120.120.130.130.11
Other Funds (Non Cash)2.940.782.386.2614.3910.26
Funds from Operations-51.50-44.64-49.37-40.44-40.54-38.08
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital7.90-12.425.662.193.44-2.41
Cash from Operating Activities-43.60-57.05-43.71-38.25-37.10-40.49
Capital Expenditures-0.03-0.06-0.00-0.030.01-0.17
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments0.000.000.000.000.000.00
Purchase of Investments0.000.000.000.000.000.00
Sale Or Maturity of Investments0.000.000.000.000.000.00
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities-0.03-0.06-0.00-0.030.01-0.17
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock123.170.00-0.36187.520.000.03
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock123.170.00-0.36187.520.000.03
Proceedsfrom Stock Options123.170.00-0.36187.520.000.03
Issuance or Reduction of Debt, Net0.000.000.000.000.000.00
Change in Long Term Debt0.000.000.00--0.00
Issuance of Long Term Debt0.000.000.00--0.00
Net Financing Active Other Cash Flow0.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.00
Cash from Financing Activities123.10-0.07-0.44187.48-0.03-0.08
Exchange Rate Effect3.784.870.15-0.48-8.31-5.81
Net Change in Cash83.25-52.32-44.00148.73-45.43-46.55
Free Cash Flow-43.63-57.11-43.71-38.28-37.09-40.66

Revenue breakdown

Revenue split-

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-307.52%2.5M33.8M797.47K
2026-10-157.34%2.5M33.6M725.67K
2026-09-305.98%2.0M33.6M736.82K
2026-09-155.40%1.8M33.1M691.37K
2026-08-316.54%2.2M33.1M514.95K
2026-08-145.37%1.8M33.1M455.63K
2026-07-313.60%1.2M33.2M427.90K
2026-07-153.44%1.1M33.1M428.27K
2026-06-303.01%1.0M32.7M357.69K
2026-06-153.43%1.1M32.7M310.14K
2026-05-292.41%0.7M29.4M272.66K
2026-05-152.05%0.6M29.4M247.69K
2026-04-303.88%1.1M27.1M188.65K
2026-04-154.24%1.1M26.6M161.39K
2026-03-312.73%0.7M26.1M163.99K
2026-03-132.84%0.7M26.1M176.64K
2026-02-272.89%0.8M26.1M264.98K
2026-02-133.00%0.8M26.1M317.86K
2026-01-302.84%0.7M26.3M330.17K
2026-01-153.44%0.9M26.3M340.36K

Option chain

expiry 2026-11-20
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call20.0012.0016.500.004.8900.000.000.850-0.4710.012
call22.509.5014.000.004.1440.000.000.820-0.4550.014
call25.007.0011.500.003.4060.000.000.786-0.4330.015
call27.504.509.303.002.79445.000.000.746-0.4030.017
call30.002.557.001.882.3223200.000.696-0.3660.019
call32.500.504.901.501.9351310.000.629-0.2940.020
call35.000.204.901.702.4781020.000.547-0.2800.021
call37.500.004.900.952.90913.000.000.508-0.3480.021
call40.000.004.900.353.20786.000.000.485-0.3840.022
call42.500.004.900.503.59113.000.000.457-0.4300.021
call45.000.004.900.123.87370.000.000.439-0.4610.021
call47.500.001.000.002.0040.000.000.192-0.1640.015
call50.000.054.900.352.23925.000.000.180-0.1770.014
call55.000.004.900.202.58110.000.000.163-0.1920.013
call60.000.004.900.202.8038.000.000.152-0.1970.013
put20.000.004.900.006.6890.000.00-0.150-0.4680.012
put22.500.004.900.105.7480.000.00-0.180-0.4520.014
put25.000.004.900.654.91711.000.00-0.214-0.4300.016
put27.500.004.901.104.1632.000.00-0.254-0.4000.017
put30.000.004.900.703.4612890.00-0.304-0.3630.019
put32.500.304.901.752.7853480.00-0.371-0.2910.020
put35.000.504.902.502.10575.000.00-0.453-0.2760.021
put37.501.556.000.001.8760.000.00-0.492-0.3440.021
put40.004.008.3012.172.1322.000.00-0.521-0.3890.021
put42.506.6010.500.002.2820.000.00-0.543-0.4250.021
put45.008.5013.000.002.5460.000.00-0.561-0.4560.021
put47.5011.0015.500.002.7830.000.00-0.808-0.1630.015
put50.0013.5018.000.003.0000.000.00-0.820-0.1720.014
put55.0018.6023.000.003.3830.000.00-0.837-0.1860.013
put60.0023.5028.0025.003.7150.000.00-0.848-0.1970.012

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-10-134Statement of changes in beneficial ownership of securities2026-10-11SEC
2026-09-254Statement of changes in beneficial ownership of securities2026-09-23SEC
2026-09-244Statement of changes in beneficial ownership of securities2026-09-22SEC
2026-09-244Statement of changes in beneficial ownership of securities2026-09-22SEC
2026-09-23144Filing for proposed sale of securities under Rule 144.SEC
2026-09-234Statement of changes in beneficial ownership of securities2026-09-21SEC
2026-09-22144/ASEC
2026-09-22144Filing for proposed sale of securities under Rule 144.SEC
2026-09-21144Filing for proposed sale of securities under Rule 144.SEC
2026-09-214Statement of changes in beneficial ownership of securities2026-09-17SEC
2026-09-214Statement of changes in beneficial ownership of securities2026-09-17SEC
2026-09-214Statement of changes in beneficial ownership of securities2026-09-17SEC
2026-09-214Statement of changes in beneficial ownership of securities2026-09-17SEC
2026-09-214Statement of changes in beneficial ownership of securities2026-09-17SEC
2026-09-214Statement of changes in beneficial ownership of securities2026-09-17SEC
2026-09-17144Filing for proposed sale of securities under Rule 144.SEC
2026-09-17144Filing for proposed sale of securities under Rule 144.SEC
2026-09-17144Filing for proposed sale of securities under Rule 144.SEC
2026-09-17144Filing for proposed sale of securities under Rule 144.SEC
2026-09-17144Filing for proposed sale of securities under Rule 144.SEC
2026-09-17144Filing for proposed sale of securities under Rule 144.SEC
2026-09-174Statement of changes in beneficial ownership of securities2026-09-15SEC
2026-09-174Statement of changes in beneficial ownership of securities2026-09-15SEC
2026-09-164Statement of changes in beneficial ownership of securities2026-09-14SEC
2026-09-15144Filing for proposed sale of securities under Rule 144.SEC
2026-09-15144Filing for proposed sale of securities under Rule 144.SEC
2026-09-154Statement of changes in beneficial ownership of securities2026-09-11SEC
2026-09-154Statement of changes in beneficial ownership of securities2026-09-14SEC
2026-09-14144Filing for proposed sale of securities under Rule 144.SEC
2026-09-14144Filing for proposed sale of securities under Rule 144.SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090020.34M17
2026-080079.69K1
2026-070080.15K1
2026-06004.19M9
2026-05002.47M10
2026-04004.60M18
2026-030000
2026-020000
2026-010000
2025-120000
2025-110000

Institutional holders

Manager% owned
FMR LLC9.91%
GENERAL ATLANTIC, L.P.9.38%
Foresite Capital Management IV, LLC6.84%
venBio Partners LLC6.65%
VIKING GLOBAL INVESTORS LP5.23%
EQT Fund Management S.a r.l.4.90%
DEERFIELD MANAGEMENT COMPANY, L.P.4.83%
Bain Capital Life Sciences Investors, LLC3.83%
WELLINGTON MANAGEMENT GROUP LLP3.43%
Polar Capital Holdings Plc3.33%

Funds

Fund% owned
Fidelity Growth Company Fund1.97%
VANGUARD HEALTH CARE FUND1.67%
Select Health Care Portfolio1.15%
Fidelity Small Cap Growth Fund0.92%
Fidelity Advisor Health Care Fund0.57%
Fidelity Growth Company K6 Fund0.57%
Fidelity Small Cap Growth K6 Fund0.47%
Fidelity Series Growth Company Fund0.46%
T. Rowe Price Health Sciences Fund, Inc.0.40%
iShares Biotechnology ETF0.30%

OakChart. PHVS. Cached 15 minutes.